ArticleNature2024
FOXO1 is a master regulator of memory programming in CAR T cells.
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 138 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed, 1 pooled it
44.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.
- Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions.Science China. Life sciences · 2026Pooled it
- Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion.Nature communications · 2024Trial
- Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles.Molecular therapy. Nucleic acids · 2026Article
- Why CD4+ T cells matter in adoptive cell therapy for solid cancers.Immuno-oncology technology · 2026Review
- TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell-CD2 Costimulatory Axis.Cancer research · 2026Article
- Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion.Nature communications · 2026Article
- T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal transduction and targeted therapy · 2026Review
- Oral nano-delivery of a gut microbial metabolite enhances T cell stemness for cancer immunotherapy.Nature nanotechnology · 2026Article
- Nicotinamide Metabolism Constrains Memory CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- T cell-nanodrug conjugates synchronize vascular normalization and immune activation for solid tumor therapy.Science advances · 2026Article
- Surfaceome CRISPR activation screening uncovers ligands regulating tumor sensitivity to NK cell killing.Nature communications · 2026Article
- Iron-ing out ferroptosis-mediated T cell dysfunction in cancer.Nature cancer · 2026Article
- Next-generation programmable cell therapies for precision medicine.Nature reviews. Genetics · 2026Review
- Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy.Biomarker research · 2026Review
- [Treatment strategies and prognostic factors for relapsed childhood acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Transcriptomic landscape of peripheral T cells following CAR-T cell therapy in diffuse large B cell lymphoma.Cancer immunology, immunotherapy : CII · 2026Article
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- SATB1 is a targetable modulator of JAK-STAT signaling and cytokines in human Treg and Tconv cells.EMBO reports · 2026Article
- Targeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer.Nature communications · 2026Article
- A platform for parallel TCR cloning and testing enables anti-neoantigen tumor immunotherapy.JCI insight · 2026Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Update of
Authors and funding
34 authors at 5 institutions in 1 country.
Alexander E Doan *Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Katherine P Mueller *Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-1873-3638
Andy Y Chen *Department of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-5018-355X
Geoffrey T RouinDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Yingshi ChenDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-5391-5103
Bence DanielDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-2410-8767
John LattinCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Martina MarkovskaDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Brett MozarskyDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jose Arias-UmanaDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-7154-4780
Robert HapkeDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
In-Young JungDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alice WangDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-1789-8561
Peng XuCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Dorota KlyszCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-6733-6110
Gabrielle ZuernDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Malek BashtiCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-0398-3367
Patrick J QuinnCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-4406-727X
Zhuang MiaoDepartment of Genetics, Stanford University, Stanford, CA, USA.
Katalin SandorDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0003-2892-4865
Wenxi ZhangDepartment of Pathology, Stanford University, Stanford, CA, USA.
Gregory M ChenCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Faith RyuDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Meghan LogunCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-7274-811X
Junior HallDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kai TanDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Stephan A GruppDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Susan E McCloryDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Caleb A LareauDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0003-4179-4807
Joseph A FraiettaCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-7900-8993
Elena SotilloCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-3993-1932
Ansuman T SatpathyDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-5167-537X
Crystal L MackallCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. cmackall@stanford.edu.ORCID 0000-0001-6323-4304
Evan W WeberDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. weberew@chop.edu.ORCID 0000-0001-5039-2899
Children's Hospital of Philadelphia · USStanford University · USGladstone Institutes · USUniversity of Pennsylvania · USParker Institute for Cancer Immunotherapy · US
Funding
Data Analysis UnitU2CCA233285 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI HUNGER, STEPHEN PATRICK, TAN, KAI · 2018 to 2023
$13.2MUnderstanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1MDefining and overcoming intrinsic T cell dysfunction to enable pediatric immunotherapyU01CA232361 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI GRUPP, STEPHAN A., WEBER, EVAN WILLIAM · 2019 to 2019
$3.7M4DN Interrogation of T Cell Exhaustion in CancerU01CA260852 · NCI · STANFORD UNIVERSITY · PI SATPATHY, ANSUMAN · 2020 to 2024
$2.6MNCI NIH HHS U01 CA232361NCI NIH HHS U01 CA260852NCI NIH HHS U2C CA233285NCI NIH HHS U54 CA232568
Abstract
A major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence of these cells in vivo
Indexed as
Forkhead Box Protein O1Immunologic MemoryImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorChromatinGene EditingHumansLymphocytes, Tumor-InfiltratingMiceT Cell Transcription Factor 1ChromatinForkhead Box Protein O1FOXO1 protein, humanReceptors, Chimeric AntigenT Cell Transcription Factor 1TCF7 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.